- Home
- TLSA vs CTMX Comparison
TLSA vs CTMX Comparison
Compare TLSA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- CTMX
- Stock Information
- Founded
- TLSA 2013
- CTMX 2008
- Country
- TLSA United Kingdom
- CTMX United States
- Employees
- TLSA N/A
- CTMX N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- CTMX Health Care
- Exchange
- TLSA Nasdaq
- CTMX Nasdaq
- Market Cap
- TLSA 85.9M
- CTMX 89.1M
- IPO Year
- TLSA 2000
- CTMX 2015
- Fundamental
- Price
- TLSA $0.90
- CTMX $1.16
- Analyst Decision
- TLSA
- CTMX Buy
- Analyst Count
- TLSA 0
- CTMX 6
- Target Price
- TLSA N/A
- CTMX $5.77
- AVG Volume (30 Days)
- TLSA 151.0K
- CTMX 694.5K
- Earning Date
- TLSA 05-10-2024
- CTMX 11-05-2024
- Dividend Yield
- TLSA N/A
- CTMX N/A
- EPS Growth
- TLSA N/A
- CTMX N/A
- EPS
- TLSA N/A
- CTMX 0.13
- Revenue
- TLSA N/A
- CTMX $119,569,000.00
- Revenue This Year
- TLSA N/A
- CTMX $1.96
- Revenue Next Year
- TLSA N/A
- CTMX N/A
- P/E Ratio
- TLSA N/A
- CTMX $8.62
- Revenue Growth
- TLSA N/A
- CTMX 50.41
- 52 Week Low
- TLSA $0.41
- CTMX $1.04
- 52 Week High
- TLSA $1.74
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- TLSA 43.74
- CTMX 48.86
- Support Level
- TLSA $0.90
- CTMX $1.12
- Resistance Level
- TLSA $0.97
- CTMX $1.19
- Average True Range (ATR)
- TLSA 0.08
- CTMX 0.05
- MACD
- TLSA -0.00
- CTMX 0.00
- Stochastic Oscillator
- TLSA 24.99
- CTMX 50.00
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.